Correa Patricia Lavatori, Mesquita Claudio T, Felix Renata M, Azevedo Jader C, Barbirato Gustavo B, Falcão Carlos Henrique, Gonzalez Constantino, Mendonça Maria Lucia, Manfrim Aquiles, de Freitas Gabriel, Oliveira Cristina C, Silva Daniel, Avila Dione, Borojevic Radovan, Alves Suzana, Oliveira Amarino C, Dohmann Hans F
Hospital Procardiaco, Rio de Janeiro, Brazil.
Clin Nucl Med. 2007 Nov;32(11):839-41. doi: 10.1097/RLU.0b013e318156b980.
To evaluate the feasibility of monitoring the autologous mononuclear bone marrow (ABMMN) cells implanted into the brain after acute ischemic stroke by the technique of labeling with Tc-99m-HMPAO.
A 37-year-old man presented with aphasia, right-side hypoesthesia, and right homonymous hemianopsia after an acute ischemic stroke of the left middle cerebral artery. He was included in an autologous bone marrow mononuclear cell-based therapy research protocol about the safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke. Nine days after the stroke he received 3.0 x 10(7) ABMMN cells delivered into the left cerebral middle artery via a balloon catheter. Approximately 1% of these cells were labeled with 150 MBq (4 mCi) Tc-99m by incubation with hexamethylpropylene amine oxime (HMPAO).
Brain perfusion images with Tc-99m ECD demonstrated hypoperfusion in the left temporal and parietal regions. The perfusion brain images were compared with tomographic views of the brain obtained 8 hours after ABMMN-labeled cell delivery, revealing intense accumulation of the ABMMN-labeled cells in the ipsilateral hemisphere. A whole-body scan was done and showed left brain, liver, and spleen uptake.
Our results showed that Tc-99m HMPAO can be used to label ABMMN cells for in vivo cell visualization, and that brain SPECT imaging with labeled ABMMN cells is a feasible noninvasive method for studying the fate of transplanted cells in vivo. Additionally, our findings demonstrate the localization of these intra-arterially injected cells.
通过用锝-99m-六甲基丙烯胺肟（Tc-99m-HMPAO）标记技术评估监测急性缺血性卒中后植入脑内的自体单核骨髓（ABMMN）细胞的可行性。
一名37岁男性在左大脑中动脉急性缺血性卒中后出现失语、右侧感觉减退和右侧同向性偏盲。他被纳入一项关于动脉内自体骨髓单核细胞移植治疗急性缺血性卒中安全性的基于自体骨髓单核细胞的治疗研究方案。卒中后9天，他通过球囊导管将3.0×10⁷个ABMMN细胞注入左大脑中动脉。其中约1%的细胞通过与六甲基丙烯胺肟（HMPAO）孵育用150MBq（4mCi）Tc-99m进行标记。
用Tc-99m乙撑双半胱氨酸（ECD）进行的脑灌注图像显示左侧颞叶和顶叶区域灌注不足。将灌注脑图像与ABMMN标记细胞注入后8小时获得的脑部断层图像进行比较，发现ABMMN标记细胞在同侧半球有强烈聚集。进行了全身扫描，显示左脑、肝脏和脾脏有摄取。
我们的结果表明，Tc-99m HMPAO可用于标记ABMMN细胞以进行体内细胞可视化，并且用标记的ABMMN细胞进行脑单光子发射计算机断层扫描（SPECT）成像是研究体内移植细胞命运的一种可行的非侵入性方法。此外，我们的研究结果证明了这些动脉内注射细胞的定位。
